Cite
Comparing the 2017 ASCO/CAP guideline for gastroesophageal adenocarcinoma surgical specimen to the 2018 ASCO/CAP guideline for breast cancer in assessing the HER2 status in primary mucinous ovarian carcinoma.
MLA
Chao, Wan-Ru, et al. “Comparing the 2017 ASCO/CAP Guideline for Gastroesophageal Adenocarcinoma Surgical Specimen to the 2018 ASCO/CAP Guideline for Breast Cancer in Assessing the HER2 Status in Primary Mucinous Ovarian Carcinoma.” Virchows Archiv : An International Journal of Pathology, vol. 480, no. 5, May 2022, pp. 1023–30. EBSCOhost, https://doi.org/10.1007/s00428-022-03285-9.
APA
Chao, W.-R., Lee, M.-Y., Lee, Y.-J., Sheu, G.-T., & Han, C.-P. (2022). Comparing the 2017 ASCO/CAP guideline for gastroesophageal adenocarcinoma surgical specimen to the 2018 ASCO/CAP guideline for breast cancer in assessing the HER2 status in primary mucinous ovarian carcinoma. Virchows Archiv : An International Journal of Pathology, 480(5), 1023–1030. https://doi.org/10.1007/s00428-022-03285-9
Chicago
Chao, Wan-Ru, Ming-Yung Lee, Yi-Ju Lee, Gwo-Tarng Sheu, and Chih-Ping Han. 2022. “Comparing the 2017 ASCO/CAP Guideline for Gastroesophageal Adenocarcinoma Surgical Specimen to the 2018 ASCO/CAP Guideline for Breast Cancer in Assessing the HER2 Status in Primary Mucinous Ovarian Carcinoma.” Virchows Archiv : An International Journal of Pathology 480 (5): 1023–30. doi:10.1007/s00428-022-03285-9.